Belgium· BE-AMP-SAM663921-00
Nemluvio 30 mg
A nemolizumab product containing nemolizumab, registered in Belgium by Galderma International. The same ATC class is registered in 14 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Nemolizumab is registered in 14 of 19 countries.
Countries holding a registration under ATC D11AH12 (nemolizumab), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 9 of them publish a price we can compare per daily dose
Nemolizumab · ATC D11AH12
14 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of nemolizumab costs, country by country.
Normalised to the WHO defined daily dose (0.8 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Nemolizumab · price per daily dose (0.8 mg)
USD · FX 28 Sept 2026
- CH Switzerland$67.16
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Nemolizumab
- Manufacturer
- Galderma International
- Country
- Belgium (BE)
- ATC code
- D11AH12
- ATC class
- Nemolizumab
- Defined daily dose
- 0.8 mg, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Nemolizumab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwedenNemluvio 30 mg Pulver och vätska till injektionsvätska, lösning i förfylld injektionspennaGalderma International
- IcelandNemluvioGalderma International
- PolandNemluvioGalderma International
- United KingdomNemluvio 30mg powder and solvent for solution for injection pre-filled pensGalderma (UK) Ltd
- NorwayNemluvioGalderma International
- SwitzerlandNemluvio 30 mg, Pulver und Lösungsmittel für Injektionslösung im FertigpenGalderma SA
- SpainNEMLUVIO 30 MG POLVO Y DISOLVENTE PARA SOLUCION INYECTABLE EN PLUMA PRECARGADAGalderma International
- CzechiaNEMLUVIOGalderma International, La Défense
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Nemluvio
- Liechtenstein · Nemluvio
- Norway · Nemluvio
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bf1659d9-20db-41af-9a60-9167800a3b99 GET /v1/drugs/bf1659d9-20db-41af-9a60-9167800a3b99?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Powder and solvent for solution for injection in pre-filled syringe",
"source": "afmps",
"status": "REVOKED",
"name_en": "Nemluvio 30 mg",
"name_fr": "Nemluvio 30 mg",
"name_nl": "Nemluvio 30 mg",
"amp_code": "SAM663921-00",
"strengths": [
"30.0000",
"30.0000",
"30.0000"
],
"pack_count": 1,
"substances": [
"Nemolizumab",
"Sucrose"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Nemolizumab",
"authorisation_numbers": [
"EU/1/24/1901/004"
]
}See everything about nemolizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.